Shareholder Class Action

Shareholders claim directors of Foundation Medicine filed a false and misleading registration statement about its proposed sale to Roche Pharmaceuticals, for $137 a share or <a href="http://www.courthousenews.com/wp-content/uploads/2018/07/SCA.pdf"><strong>$2.4 billion</strong></a>, in a federal class action.

WILMINGTON, Del. — Shareholders claim directors of Foundation Medicine filed a false and misleading registration statement about its proposed sale to Roche Pharmaceuticals, for $137 a share or $2.4 billion , in a federal class action.

Categories / Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.